BET inhibition as a new strategy for the treatment of gastric cancer
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to th...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Impacta Journals
2016
|
| _version_ | 1826287185382342656 |
|---|---|
| author | Montenegro, R Clark, P Howarth, A Wan, X Ceroni, A Siejka, P Nunez-Alonso, G Monteiro, O Rogers, C Gamble, V Burbano, R Brennan, P Tallant, C Ebner, D Fedorov, O O'Neill, E Knapp, S Dixon, D Müller, S |
| author_facet | Montenegro, R Clark, P Howarth, A Wan, X Ceroni, A Siejka, P Nunez-Alonso, G Monteiro, O Rogers, C Gamble, V Burbano, R Brennan, P Tallant, C Ebner, D Fedorov, O O'Neill, E Knapp, S Dixon, D Müller, S |
| author_sort | Montenegro, R |
| collection | OXFORD |
| description | Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer. |
| first_indexed | 2024-03-07T01:54:50Z |
| format | Journal article |
| id | oxford-uuid:9b5a6076-b144-48bf-8c20-d77e24273482 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:54:50Z |
| publishDate | 2016 |
| publisher | Impacta Journals |
| record_format | dspace |
| spelling | oxford-uuid:9b5a6076-b144-48bf-8c20-d77e242734822022-03-27T00:28:14ZBET inhibition as a new strategy for the treatment of gastric cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9b5a6076-b144-48bf-8c20-d77e24273482EnglishSymplectic Elements at OxfordImpacta Journals2016Montenegro, RClark, PHowarth, AWan, XCeroni, ASiejka, PNunez-Alonso, GMonteiro, ORogers, CGamble, VBurbano, RBrennan, PTallant, CEbner, DFedorov, OO'Neill, EKnapp, SDixon, DMüller, SGastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer. |
| spellingShingle | Montenegro, R Clark, P Howarth, A Wan, X Ceroni, A Siejka, P Nunez-Alonso, G Monteiro, O Rogers, C Gamble, V Burbano, R Brennan, P Tallant, C Ebner, D Fedorov, O O'Neill, E Knapp, S Dixon, D Müller, S BET inhibition as a new strategy for the treatment of gastric cancer |
| title | BET inhibition as a new strategy for the treatment of gastric cancer |
| title_full | BET inhibition as a new strategy for the treatment of gastric cancer |
| title_fullStr | BET inhibition as a new strategy for the treatment of gastric cancer |
| title_full_unstemmed | BET inhibition as a new strategy for the treatment of gastric cancer |
| title_short | BET inhibition as a new strategy for the treatment of gastric cancer |
| title_sort | bet inhibition as a new strategy for the treatment of gastric cancer |
| work_keys_str_mv | AT montenegror betinhibitionasanewstrategyforthetreatmentofgastriccancer AT clarkp betinhibitionasanewstrategyforthetreatmentofgastriccancer AT howartha betinhibitionasanewstrategyforthetreatmentofgastriccancer AT wanx betinhibitionasanewstrategyforthetreatmentofgastriccancer AT ceronia betinhibitionasanewstrategyforthetreatmentofgastriccancer AT siejkap betinhibitionasanewstrategyforthetreatmentofgastriccancer AT nunezalonsog betinhibitionasanewstrategyforthetreatmentofgastriccancer AT monteiroo betinhibitionasanewstrategyforthetreatmentofgastriccancer AT rogersc betinhibitionasanewstrategyforthetreatmentofgastriccancer AT gamblev betinhibitionasanewstrategyforthetreatmentofgastriccancer AT burbanor betinhibitionasanewstrategyforthetreatmentofgastriccancer AT brennanp betinhibitionasanewstrategyforthetreatmentofgastriccancer AT tallantc betinhibitionasanewstrategyforthetreatmentofgastriccancer AT ebnerd betinhibitionasanewstrategyforthetreatmentofgastriccancer AT fedorovo betinhibitionasanewstrategyforthetreatmentofgastriccancer AT oneille betinhibitionasanewstrategyforthetreatmentofgastriccancer AT knapps betinhibitionasanewstrategyforthetreatmentofgastriccancer AT dixond betinhibitionasanewstrategyforthetreatmentofgastriccancer AT mullers betinhibitionasanewstrategyforthetreatmentofgastriccancer |